Vazobral (Vasobral)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbsporal solution
Composition:

1 ml of the solution contains:

Active components:

Dihydroergocryptine α-Mesylate 1.0 mg

Caffeine 10.0 mg

Excipients:

Citric acid monohydrate, ethanol, glycerin, water for injection.
Description:A clear, colorless or pale yellow solution with the smell of alcohol.
Pharmacotherapeutic group:Vasodilator
ATX: & nbsp
  • Ergoloid mesylate in combination with other drugs
    • Pharmacodynamics:

    Combined drug, α-Dihydroergocryptin is a dihydrated ergot derivative, blocks α1 and α2 adrenergic receptors. It acts dopaminergic, serotonergic, reduces aggregation of platelets and erythrocytes, reduces the permeability of the vascular wall, increases the number of functioning capillaries, improves blood circulation and metabolic processes in the brain, increases the resistance of brain tissue to hypoxia.

    Caffeine has a psychostimulating and analeptic effect, enhances the processes of excitation in the cerebral cortex - increases mental and physical performance, reduces fatigue and drowsiness, increases the reflex excitability of the spinal cord, excites the respiratory and vasomotor centers, and has a diuretic effect.

    Pharmacokinetics:

    When taken orally, the absorption of dihydroergocryptin is accelerated in the presence of caffeine (the time to reach the maximum concentration in the blood plasma is 0.5 hours).

    Maximum concentration after oral administration of 8 mg α- dihydroergocryptin is 227 pg / ml, and the half-life is less than 2 hours.

    Indications:

    • reduction of mental activity, violation of attention and memory, violation of orientation in space, caused by age-related changes;
    • cerebrovascular insufficiency (including due to cerebral atherosclerosis);
    • consequences of cerebral circulation;
    • prevention of migraine;
    • vestibular and labyrinthine disorders (dizziness, tinnitus, hypoacusia) ischemic origin;
    • Meniere's disease;
    • retinopathy (diabetic and hypertensive);
    • violations of peripheral arterial blood circulation (syndrome and Raynaud's disease);
    • venous insufficiency.
    Contraindications:

    Increased individual sensitivity to the components of the drug.

    Pregnancy and lactation:

    There are no clinical data on the use of Vazobrala during pregnancy and lactation. The use of the drug in the period of breastfeeding can lead to a decrease in lactation.

    Dosing and Administration:

    Inside (during meals, with a small amount of liquid) for 2-4 ml (1-2 dosing syringe) 2 times a day. The duration of the course of treatment is 2-3 months, if necessary, treatment courses can be repeated.

    Side effects:

    From the gastrointestinal tract: nausea, gastralgia, dyspepsia, with these manifestations, drug withdrawal is not required. Rarely (no more than 1% of cases) - dizziness, agitation, headache. Very rarely (no more than 0.1 % cases), allergic reactions are possible, tachycardia, lowering blood pressure.

    Overdose:

    Symptoms - increased severity of side effects. Treatment is symptomatic.

    Interaction:

    With the simultaneous appointment of Vasobrail and hypotensive drugs, it is possible to develop arterial hypotension. Caffeine weakens the effect of hypnotics.

    Special instructions:Vasobrail has a vasodilating effect, without affecting the systemic blood pressure. The appointment of Vasobrail to patients with hypertension does not exclude the need for the use of antihypertensive agents. Contained in the preparation caffeine can cause sleep disturbance, tachycardia.
    Form release / dosage:Solution for oral administration.
    Packaging:

    To 50 ml in a bottle of dark glass, along with instructions for use and a dispensing syringe in a cardboard box.

    Storage conditions:

    At a temperature 15-25 ° C, out of the reach of children.

    Shelf life:

    3 years. Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:П N014499 / 01
    Date of registration:27.08.2010 / 02.04.2013
    Expiration Date:Unlimited
    The owner of the registration certificate:Chiesi Pharmaceuticals Ltd.Chiesi Pharmaceuticals Ltd.
    Manufacturer: & nbsp
    Representation: & nbspChiesi Pharmaceuticals Ltd.Chiesi Pharmaceuticals Ltd.
    Information update date: & nbsp10.01.2017
    Illustrated instructions
      Instructions
      Up